Medical expert of the article
New publications
Preparations
Recormon
Last reviewed: 03.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Indications Recormona
It is used for symptomatic treatment of anemia that accompanies certain conditions:
- tumors in people undergoing chemotherapy;
- lymphocytic leukemia or myeloma in people undergoing anticancer treatment;
- chronic renal failure;
- various chronic diseases.
Release form
The substance is released in the form of a solution, inside syringe tubes used for intravenous or subcutaneous administration.
Pharmacodynamics
The recombinant drug is similar in its biological parameters and chemical structure to human erythropoietin, which regulates the processes of erythropoiesis.
The medicine increases the number of red blood cells, as well as hemoglobin levels. At the same time, it does not affect the processes of leukopoiesis. If there is a lack of iron in the body, it is used in combination with iron products. It does not have a cytotoxic effect on human bone marrow.
Erythropoietin endings sometimes appear on the surface of tumor cells. It cannot be ruled out that medications that stimulate erythropoiesis processes also increase the activity of malignant neoplasm growth.
Recormon must be administered subcutaneously or intravenously, because the substance is destroyed when it enters the gastrointestinal tract.
Pharmacokinetics
After subcutaneous injection, the drug is absorbed for quite a long time, reaching Cmax values after 12-28 hours. The level of bioavailability of the drug after subcutaneous injection is within 23-42%.
With intravenous administration, the half-life of the substance is 4-12 hours, and with subcutaneous injection it increases to a mark in the range of 13-28 hours.
Dosing and administration
The medicine should be administered intravenously or subcutaneously. The syringe tube is ready for use immediately from the package.
Anemia in people with kidney pathologies.
For people undergoing hemodialysis procedures, the drug is administered through an arteriovenous shunt, after the completion of the treatment session. For people who do not undergo hemodialysis procedures, the solution is administered subcutaneously.
At the initial stage of therapy, the dosage is selected. For subcutaneous injections, 20 IU/kg is required, administered 3 times a week. For intravenous injections, 40 IU/kg is required, also administered 3 times a week. The maximum weekly dose for any injection method should not exceed 720 IU/kg.
The therapy is carried out to achieve hemoglobin values of 100-120 g/l. Then the minimum maintenance dosage is selected, which is sufficient to achieve the desired effect. The weekly dose is administered in 1 or 3 doses. After the patient's condition has stabilized, they are transferred to a single administration of the drug with 2-week intervals between procedures. The treatment should be carried out over a long period.
Anemia in people undergoing chemotherapy.
The initial dose is 450 IU/kg per week, administered subcutaneously, in one injection or in 3 doses. After reaching certain hemoglobin values, the dose is reduced by 25-50%. Then the therapy is continued for another month after the completion of the chemotherapy course.
Use in children.
Therapy in children should be started with a standard dosage portion. To prevent the development of anemia in premature infants, the drug is administered only through syringe tubes. Therapy begins on the 3rd day after birth and continues until 1.5 months. The administration is performed subcutaneously, 250 IU/kg 3 times a week.
It is important to remember that only transparent injection liquid, which does not contain any inclusions, is suitable for administration. Any residues of the substance not used during administration of the medicinal portion cannot be reused. For this reason, patients with low weight should be administered the drug in portions of 2000 or 1000 IU.
Before starting therapy, iron deficiency must be ruled out; iron supplements may be prescribed.
[ 6 ]
Use Recormona during pregnancy
There is data on the prescription of the drug after the 20th week of pregnancy for iron deficiency anemia and decreased production of erythropoietin. Its use in this case is considered appropriate, because Recormon helps deliver the iron taken by the woman into the bone marrow, where the enhanced process of erythropoiesis occurs.
Contraindications
Main contraindications:
- recent myocardial infarction;
- DVT or angina;
- marked increase in blood pressure values;
- presence of hypersensitivity to the drug.
Caution is required when prescribing to people with epilepsy, thrombocytosis or refractory anemia in which blast-transformed cells are observed.
Side effects Recormona
The use of Recormon may lead to the following disorders:
- increased blood pressure, hypertensive crisis accompanied by encephalopathy (speech disorders, headaches, tonic-clonic seizures and gait disturbances);
- headaches;
- increased platelet count or thrombocytosis;
- decreased ferritin values and increased hemoglobin levels, hyperphosphatemia or temporary hyperkalemia;
- rash, anaphylactoid symptoms, urticaria or itching;
- flu-like symptoms (at the initial stage of treatment): chills, headaches, fever, feeling of malaise and pain in the bones;
- symptoms at the injection site.
[ 5 ]
Overdose
In case of intoxication, excessive erythropoiesis develops, which results in complications in the cardiovascular system that are life-threatening.
If high hemoglobin levels are observed, the drug should be discontinued temporarily.
Storage conditions
Recormon can be kept at temperatures ranging from 2-8°C.
Shelf life
Recormon can be used within 24 months from the date of release of the therapeutic drug.
Application for children
The medication is not prescribed to children under 3 years of age.
Analogues
Analogues of the drug are such medications as Epostim, Vero-Epoetin, and also Epoetin with Erythrostim.
Reviews
Recormon receives quite positive reviews. The drug is generally well tolerated, but only when used in recommended doses. However, when administering excessively large doses, side effects appear: increased blood pressure, chest pain, dizziness with headaches. Thrombosis or seizures also sometimes develop.
Attention!
To simplify the perception of information, this instruction for use of the drug "Recormon" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.